STML - Stemline Therapeutics, Inc.
| Previous Close | 17.00 |
| Open | 17.00 |
| Bid | 17.40 x 1200 |
| Ask | 17.55 x 1000 |
| Day's Range | 17.00 - 17.85 |
| 52 Week Range | 10.20 - 20.55 |
| Volume | 59,898 |
| Avg. Volume | 160,857 |
| Market Cap | 495.746M |
| Beta | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•16 days ago
Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Sept. 05, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will ...
- GlobeNewswire•last month
Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
NEW YORK, Aug. 14, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will ...
- GlobeNewswire•last month
Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review
Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET. NEW YORK, Aug. 13, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical ...
- GlobeNewswire•last month
Stemline Therapeutics Reports Second Quarter 2018 Financial Results
NEW YORK, Aug. 09, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today its financial results for the quarter ended June ...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Stemline Therapeutics, Silgan, CVR Energy, MINDBODY, FireEye, and Quality — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stemline ...
- GlobeNewswire•3 months ago
Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN
NEW YORK, June 25, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has completed submission of a rolling Biologics ...
- ACCESSWIRE•3 months ago
Biotechnology Firm PPCB, Shows Great Potential
Propanc BioPharma, Inc ( PPCB ) Market Cap: 2.4 M, current share price: $0.07 HENDERSON, NV / ACCESSWIRE / June 19, 2018 / Propanc Biopharma Inc. , a clinical stage biopharmaceutical company focusing on ...
- ACCESSWIRE•4 months ago
Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Stemline Therapeutics, Inc. (NASDAQ: STML), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On May 18, 2018, the Company announced that its SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal blastic plasmacytoid dendritic cell neoplasm (BPDCN) program, at the upcoming 23rd Congress of the European Hematology Association (EHA), to be held from June 14-17, 2018, in Stockholm, Sweden. Updated data from the ongoing Phase-2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented.
- Business Wire•5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Stemline Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
- PR Newswire•5 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , May 1, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
- ACCESSWIRE•5 months ago
Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401
Stock Monitor: Cyclacel Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML ...